BioCentury | Aug 25, 2020
Product Development

Aug. 24 Quick Takes: Setbacks for Novartis, Odonate, Onconova, Tricida; plus upcoming adcomm for Alkermes, and Sinopharm’s vaccine

...– Programmed cell death 1 PI3K - Phosphoinositide 3-kinase PLK1 (STPK13) - Polo-like kinase 1 BC Staff spartalizumab (PDR001) tesetaxel...
BioCentury | Jul 11, 2019
Targets & Mechanisms

The tumor stroma rises as the newest source of immuno-oncology targets

...Eli Lilly ) Solid tumors Phase I Novartis AG (NYSE:NVS; SWX:NOVN) NIS793 Anti-TGFβ1 mAb spartalizumab (PDR001...
BioCentury | Oct 26, 2018
Clinical News

Latest immuno-oncology monotherapy data continue to cast doubt on combo strategies

...ipilimumab from Bristol-Myers Squibb Co. (NYSE:BMY), and the other in combination with anti-PD-1 mAb spartalizumab (PDR001...
...Treat advanced solid tumors or lymphomas Endpoint: Safety Status: Phase I data Milestone: NA BC Staff ADU-S100, MIW815 MK-1454 PDR001 PEG-IL-10...
BioCentury | Oct 22, 2018
Clinical News

Latest immuno-oncology monotherapy data continue to cast doubt on combo strategies

...ipilimumab from Bristol-Myers Squibb Co. (NYSE:BMY), and the other in combination with anti-PD-1 mAb spartalizumab (PDR001...
...be taken into large Phase III trials (see “Lessons from the Echo Chamber” ). BC Staff ADU-S100, MIW815 MK-1454 PDR001 PEG-IL-10...
BioCentury | Dec 14, 2017
Clinical News

Aduro discontinues development of CRS-207

...tumors or lymphomas -- one as monotherapy and the other in combination with anti-PD-1 antibody PDR001...
...human mesothelin Indication: Treat mesothelioma and ovarian cancer Endpoint: NA Status: Development discontinued Milestone: NA Allison Johnson ADU-S100 CRS-207 epacadostat Keytruda PDR001 Aduro...
BioCentury | Dec 13, 2017
Clinical News

Aduro discontinues development of CRS-207

...tumors or lymphomas -- one as monotherapy and the other in combination with anti-PD-1 antibody PDR001...
...program (see BioCentury Innovations, Oct. 5) . Aduro was up $0.40 to $8.25 on Tuesday. Allison Johnson ADU-S100 CRS-207 epacadostat Keytruda PDR001 Aduro...
BioCentury | Oct 6, 2017
Finance

Coasting on catalysts

...Lead program ADU-S100 is in a Phase Ib trial in combination with Novartis' PD-1 antibody PDR001...
BioCentury | Sep 16, 2017
Strategy

Passing the baton

...first-in-class immuno-oncology combinations this year. All of these combination studies would include Novartis’ PD-1 inhibitor PDR001...
...ClinicalTrials.gov, which lists 18 trials combining PDR001 with novel immunotherapy agents. Novartis is also testing PDR001...
BioCentury | Jul 28, 2016
Targets & Mechanisms

Making sense of sensors

...the partnership with Novartis will allow Aduro to combine ADU-S100 with the pharma's PD-1 antibody PDR001...
Items per page:
1 - 9 of 9